Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Tango Therapeutics has appointed Malte Peters as the new CEO, succeeding Barbara Weber, who served as CEO until last Thursday [2][3] - Barbara Weber will continue to serve as Executive Chairman and has been instrumental in the company's development since its inception [2][3] Leadership Transition - Malte Peters has a strong background in the pharmaceutical industry, having previously served as Chief R&D Officer at MorphoSys, which is relevant to Tango's future development needs [3] - The leadership change is part of a strategic move as the company prepares to advance its key drug, vopimetostat, which is considered crucial for the company's future [4]